4-1BB - Immune Checkpoint Mouse Models - Mouse Repository - Animal Models - Research

SKU :
ASHU-190077
Catalog # :
ASHU-190077
Availability :
Mouse
Humanized Strategy Humanized 4-1BB Expression on Spleen-derived Activated T Cells Figure 1. Expression of humanized CD137 (4-1BB) in the activated spleen lymphocytes of heterozygous humanized 4-1BB mice is detected by FACS.  The spleen lymphocytes of heterozygous humanized 4-1BB mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. The expression of humanized 4-1BB was detected by FACS. The results showed that the active expression of human .....
Inquire
Questions ? Contact Us
Strain Information
  • Catalog Number ASHU-190077
  • Strain Name C57BL/6J-Tnfrsf9tm2(TNFRSF9)Asc
  • Mutation Type Humanization
  • GENE Synonyms ILA, Ly63, 4-1BB, Cd137, CDw137, AA408498, AI325004, A930040I11Rik
  • Human Orthologs TNFRSF9
  • Emsamble ID ENSMUSG00000028965
  • MGI ID 1101059
  • NCBI ID 21942
  • Coat Color Black
  • Mutation Type Humanization
Description

Humanized Strategy

Landingpage-ASHU-190077-4-1BB-HU-ICPMouse-1

Humanized 4-1BB Expression on Spleen-derived Activated T Cells

Landingpage-ASHU-190077-4-1BB-HU-ICPMouse-2.01

Figure 1. Expression of humanized CD137 (4-1BB) in the activated spleen lymphocytes of heterozygous humanized 4-1BB mice is detected by FACS. 

The spleen lymphocytes of heterozygous humanized 4-1BB mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. The expression of humanized 4-1BB was detected by FACS. The results showed that the active expression of humanized 4-1BB can be detected in both activated CD4+ and CD8+ T lymphocytes collected from heterozygous humanized 4-1BB mice.

 (Data in partnership with collaborators)

Landingpage-ASHU-190077-4-1BB-HU-ICPMouse.3 

Figure 2.In vivo validation of humanized 4-1BB mice. Humanized 4-1BB mice were inoculated with MC38 colon cancer cells, and were randomly assigned into different groups (n=6) when the tumors grew to a volume of 100 mm3. Human-specific, 4-1BB antibody ( Urelumab or Utomilumab) was given every three days (Q3D) for two weeks.

(Data in partnership with collaborators)

Research Application
Immunotherapy, Cancer research, Drug screening
Availability
Mouse
Google